Published in Pharmacoeconomics on June 01, 2014
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings. Am J Cardiovasc Drugs (2014) 0.79
A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation. Cardiol Ther (2016) 0.78
The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015. Acta Pharm Sin B (2016) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ (2001) 6.48
Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. Value Health (2003) 6.02
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med (2010) 4.01
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J (2012) 3.66
The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J (2001) 3.07
Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ (2005) 2.52
Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract (2011) 2.25
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost (2011) 2.22
Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J (2008) 2.09
Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost (2011) 2.01
Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review. Int J Technol Assess Health Care (2006) 1.91
Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol (2004) 1.77
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making (2012) 1.61
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke (2013) 1.37
Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke (2003) 1.33
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health (2013) 1.29
Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost (2011) 1.23
Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess (2007) 1.17
How sensitive are cost-effectiveness analyses to choice of parametric distributions? Med Decis Making (2005) 1.10
Decreasing trends in the incidence of heart failure after acute myocardial infarction from 1993-2004: a study of 175,216 patients with a first acute myocardial infarction in Sweden. Eur J Heart Fail (2010) 1.09
New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. Eur Heart J (2008) 1.06
Quality-adjusted life expectancy (QALE) and loss of QALE for patients with ischemic stroke and intracerebral hemorrhage: a 13-year follow-up. Stroke (2010) 1.06
Survival after stroke--the impact of CHADS2 score and atrial fibrillation. Int J Cardiol (2009) 1.01
Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010. Pharmacoeconomics (2014) 1.01
Stroke incidence and mortality rates 1987 to 2006 related to secular trends of cardiovascular risk factors in Gothenburg, Sweden. Stroke (2009) 0.97
Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. Qual Life Res (2010) 0.95
Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One (2013) 0.93
The time course of subsequent hospitalizations and associated costs in survivors of an ischemic stroke in Canada. BMC Health Serv Res (2006) 0.92
Subgroup analyses. BMJ (2012) 0.87
Nonpharmacologic measures and drug compliance in patients with heart failure: data from the EuroHeart Failure Survey. Am J Cardiol (2007) 0.84
No impact of atrial fibrillation on mortality risk in optimally treated heart failure patients. Clin Cardiol (2011) 0.84
Atrial fibrillation, physical activity and endurance training. Tidsskr Nor Laegeforen (2012) 0.82
Cost-effectiveness acceptability curves revisited. Pharmacoeconomics (2013) 0.78
[Hospital admission rates for cardiovascular diseases in Western Norway, 1992-2001]. Tidsskr Nor Laegeforen (2008) 0.76
Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open (2012) 1.20
Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer (2011) 1.07
Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010. Pharmacoeconomics (2014) 1.01
Health technology assessment to optimize health technology utilization: using implementation initiatives and monitoring processes. Int J Technol Assess Health Care (2010) 0.97
Interactions between health technology assessment, coverage, and regulatory processes: emerging issues, goals, and opportunities. Int J Technol Assess Health Care (2011) 0.93
Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry. Int J Technol Assess Health Care (2012) 0.86
Modeling the impact of screening policy and screening compliance on incidence and mortality of cervical cancer in the post-HPV vaccination era. J Public Health (Oxf) (2012) 0.85
New anticoagulants as thromboprophylaxis after total hip or knee replacement. Int J Technol Assess Health Care (2013) 0.80
Correction: Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis. PLoS One (2016) 0.75